Anticancer Drugs Practice Questions

Q: SIADH is associated with which of the following drugs?

Vincristine. ***Vincristine*** - **Vincristine** is a well-known chemotherapeutic agent associated with inducing **SIADH (Syndrome of Inappropriate Antidiuretic Hormone)** secretion. - This side effect is thought to be due to its **neurotoxic effects**, specifically on the hypothalamus or posterior pituitary, leading to increased ADH release. *Erythromycin* - **Erythromycin** is a macrolide antibiotic primarily known for its gastrointestinal side effects like nausea, vomiting, and abdominal cramps due to its action as a **motilin receptor agonist**. - It is not commonly associated with SIADH, although prolonged use in sensitive individuals might cause other electrolyte disturbances, but not typically hyponatremia from SIADH. *5-FU* - **5-fluorouracil (5-FU)** is an antimetabolite chemotherapy drug with common side effects including myelosuppression, mucositis, and dermatological reactions like hand-foot syndrome. - While it can cause various systemic toxicities, **SIADH is not a recognized or common side effect** of 5-FU. *Methotrexate* - **Methotrexate** is an antifolate chemotherapy and immunosuppressant drug that can cause significant side effects such as myelosuppression, nephrotoxicity, hepatotoxicity, and mucositis. - Although it can lead to kidney damage and fluid retention, **SIADH is not typically associated with methotrexate** use.

Q: Which drug has been used in the treatment of anaplastic thyroid carcinoma despite limited efficacy?

Doxorubicin. ***Doxorubicin*** - While anaplastic thyroid carcinoma is often **highly resistant to chemotherapy**, doxorubicin has shown some limited efficacy in studies, making it one of the systemic agents sometimes used to attempt to control disease progression. - It works as an **anthracycline antibiotic** that intercalates DNA, inhibiting macromolecular biosynthesis and causing cell death. *5-Fluorouracil* - **5-FU** is primarily used in the treatment of various **gastrointestinal cancers** (e.g., colorectal, gastric, pancreatic) and some breast cancers. [1] - Its mechanism involves inhibiting **thymidylate synthase**, thereby disrupting DNA synthesis; however, it has minimal activity against anaplastic thyroid carcinoma. [1] *Methotrexate* - **Methotrexate** is a **folate antagonist** mainly used in the treatment of leukemia, lymphomas, and autoimmune diseases like rheumatoid arthritis and psoriasis. [2] - It is not considered a standard or effective treatment for anaplastic thyroid carcinoma. [2] *Vinblastine* - **Vinblastine** is a **vinca alkaloid** that inhibits microtubule formation, arresting cells in metaphase; it is commonly used in Hodgkin lymphoma, non-small cell lung cancer, and testicular cancer. - It has limited to no role in the treatment of anaplastic thyroid carcinoma.

Q: Denileukin diftitox binds to which receptor?

IL-2 receptor. ***IL-2 receptor*** - Denileukin diftitox is a **fusion protein** consisting of human **interleukin-2 (IL-2)** and diphtheria toxin fragments. - Its mechanism of action relies on binding to the **high-affinity IL-2 receptor (CD25)** found on the surface of some cancer cells, particularly those in cutaneous T-cell lymphoma, delivering the toxin for cell apoptosis. *IL-1 receptor* - The **IL-1 receptor** mediates the effects of interleukin-1, a pro-inflammatory cytokine, and its binding is not a mechanism for denileukin diftitox. - Denileukin diftitox is specifically designed to target the IL-2 pathway, not the IL-1 pathway, for cancer treatment. *IL-4 receptor* - The **IL-4 receptor** is involved in allergic responses and immune regulation, primarily binding interleukin-4. - Denileukin diftitox is engineered to exploit the IL-2 signaling pathway for therapeutic effect, not the IL-4 pathway. *IL-5 receptor* - The **IL-5 receptor** is important for the development and function of eosinophils, mediating the effects of interleukin-5. - Denileukin diftitox's therapeutic utility is linked to its specific interaction with the IL-2 receptor, which is distinct from the IL-5 receptor.

Q: Use of tamoxifen for breast cancer can cause all of the following adverse effects, except which of the following?

Carcinoma in contralateral breast. ***Carcinoma in contralateral breast*** - Tamoxifen is an **estrogen receptor modulator** used in breast cancer treatment, and it reduces the risk of new primary breast cancers, including in the contralateral breast. - Its mechanism of action involves **blocking estrogen effects** in breast tissue, thus preventing estrogen-dependent tumor growth and recurrence. *Thromboembolism* - Tamoxifen has **estrogenic effects** in some tissues, increasing the risk of thrombotic events like **deep vein thrombosis** and **pulmonary embolism**. - This adverse effect is a significant concern, particularly in older patients or those with pre-existing risk factors for clotting. *Endometrial carcinoma* - Tamoxifen acts as a **partial estrogen agonist** in the uterus, stimulating endometrial proliferation. - This proliferative effect can lead to an increased risk of developing **endometrial hyperplasia** and **carcinoma**. *Cataract* - Tamoxifen use has been associated with an increased risk of **cataract formation** and other ocular toxicities. - Patients undergoing tamoxifen therapy should have **regular ophthalmological examinations** to monitor for these potential side effects.

Q: Which of the following chemotherapeutic agents can be administered orally?

Capecitabine. ***Capecitabine*** - **Capecitabine** is a **prodrug** that is converted into **5-fluorouracil (5-FU)** in the body, which then exerts its cytotoxic effect. - Its oral bioavailability allows for **convenient outpatient administration**, unlike many other chemotherapeutic agents [1].*Cytarabine* - **Cytarabine** (Ara-C) is primarily administered intravenously or subcutaneously due to its **poor oral absorption** and rapid deamination in the gastrointestinal tract. - It is a **pyrimidine analog** mainly used in acute myeloid leukemia and lymphomas.*Actinomycin D* - **Actinomycin D** (dactinomycin) is a powerful antitumor antibiotic derived from *Streptomyces parvullus* and is given via **intravenous injection**. - Its cytotoxic effects stem from its ability to **intercalate DNA** and inhibit RNA synthesis, which necessitates parenteral administration.*Doxorubicin* - **Doxorubicin**, an **anthracycline antibiotic**, is administered intravenously because it has **poor oral bioavailability** and is extensively metabolized if taken orally. - It is known for its **cardiotoxicity** and is used in a wide range of cancers, including breast cancer, lymphomas, and sarcomas.

Q: Which of the following can be given orally?

Cyclophosphamide. ***Cyclophosphamide*** - **Cyclophosphamide** is an **alkylating agent** that can be administered both **orally and intravenously**. - It has good **oral bioavailability** (>75%) and is commonly given orally in many chemotherapy regimens and immunosuppressive protocols. - Oral formulation is particularly useful for maintenance therapy and chronic administration. *Actinomycin D* - **Actinomycin D** (dactinomycin) is an **intravenous** antineoplastic agent. - It is a **peptide-containing antibiotic** that intercalates into DNA, and its oral bioavailability is very poor. *Cytosine arabinoside* - **Cytosine arabinoside** (cytarabine) is primarily administered **intravenously** or **subcutaneously**. - It has a high first-pass metabolism when given orally, resulting in very **low oral bioavailability**. *Doxorubicin* - **Doxorubicin** is an **anthracycline antibiotic** that is predominantly given **intravenously**. - It has poor oral bioavailability due to extensive **first-pass metabolism** and is therefore not administered orally.

Q: Tamoxifen is primarily indicated for reducing the risk of which type of cancer?

Breast. ***Breast***- **Tamoxifen** is a **selective estrogen receptor modulator (SERM)** specifically used in **estrogen receptor-positive (ER+) breast cancer** [1, 2].It acts as an **estrogen antagonist** in breast tissue, thereby **reducing breast cancer recurrence and risk** [1].This is its **primary and most important clinical indication** [1, 2].*Endometrium*- While tamoxifen is effective against breast cancer, it acts as an **estrogen agonist** in the endometrial tissue [1].This **estrogenic effect** paradoxically **increases the risk** of developing **endometrial cancer** as a side effect [1].Therefore, it is **not indicated** for endometrial cancer prevention [1].*Ovary*- Tamoxifen has **no primary indication** for the prevention or treatment of **ovarian cancer**.Its mechanism of action is not relevant to the typical pathogenesis of ovarian malignancies.*All of the options*- This option is incorrect because tamoxifen **does not reduce the risk of all listed cancers**.It specifically **increases** the risk of endometrial cancer rather than reducing it [1].Its beneficial effects are primarily observed in **estrogen receptor-positive breast cancer** only [1, 2].

Q: Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?

Cisplatin. ***Cisplatin*** - **Cisplatin** is a platinum-based chemotherapy drug that forms **DNA cross-links**, inhibiting DNA synthesis and leading to the death of rapidly dividing cells, making it highly effective against **ovarian carcinoma**. - It is a cornerstone of chemotherapy regimens for ovarian cancer, often used in combination with other agents such as paclitaxel. *Methotrexate* - **Methotrexate** is an **antimetabolite** that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis. - While it is used in various cancers like leukemia, lymphoma, and some solid tumors (e.g., breast cancer, gestational trophoblastic disease), it is **not a primary recommended drug for ovarian carcinoma**. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that causes DNA damage, leading to cell death. - It is used in many cancers, including lymphoma, breast cancer, and some leukemias, but it is **not a first-line or primary agent for ovarian carcinoma** in contemporary treatment guidelines. *Dacarbazine* - **Dacarbazine** is an **alkylating agent** primarily used in the treatment of **malignant melanoma** and Hodgkin lymphoma. - It is **not indicated for the treatment of ovarian carcinoma**.

Q: Which one of the following can cause agranulocytosis most commonly?

Alkylating agents. ***Alkylating agents*** - Among the given options, alkylating agents are the **most likely to cause severe neutropenia/agranulocytosis** due to their mechanism of action. - These chemotherapeutic drugs **directly damage bone marrow stem cells**, causing dose-dependent **myelosuppression** affecting all cell lines, including severe reduction in neutrophil production. - Their mechanism involves **cross-linking DNA and interfering with DNA replication**, which is particularly detrimental to rapidly dividing hematopoietic cells. - **Clinical note:** While classic drug-induced agranulocytosis is more associated with drugs like clozapine, carbamazepine, or antithyroid medications, alkylating agents cause the most severe and predictable bone marrow suppression among these options. *Corticosteroids* - Corticosteroids cause **leukocytosis** (increased white blood cells), not agranulocytosis. - They work by **demarginating neutrophils** from vessel walls and decreasing their migration into tissues. - They may suppress lymphocytes and eosinophils but do **not cause agranulocytosis**. *Paracetamol* - Paracetamol is **not associated with agranulocytosis** as a recognized adverse effect. - Its primary toxicity concern is **dose-dependent hepatotoxicity** due to glutathione depletion and formation of toxic metabolite NAPQI. - Hematological adverse effects are extremely rare. *Endotoxemia* - Endotoxemia (associated with gram-negative bacterial sepsis) typically causes **leukocytosis with left shift** (increased immature neutrophils). - The body mounts an immune response with **neutrophil activation and release**, not suppression. - While severe prolonged sepsis can affect bone marrow, the typical response is increased, not decreased, neutrophil count.

Q: The use of which of the following helps in reducing the toxicity of doxorubicin to the heart?

Dexrazoxane. ***Dexrazoxane*** - **Dexrazoxane** is a **cardioprotective agent** that chelates intracellular iron, thereby reducing the formation of **free radicals** responsible for doxorubicin-induced cardiotoxicity. - It is specifically approved for reducing the incidence and severity of **cardiomyopathy** associated with doxorubicin use, particularly in patients who have received a high cumulative dose. *Amifostine* - **Amifostine** is a **cytoprotective agent** used to reduce the incidence of nephrotoxicity associated with platinum-based chemotherapy (e.g., cisplatin) and to reduce xerostomia in patients undergoing radiation therapy for head and neck cancer. - Its primary mechanism involves scavenging **free radicals** and detoxifying reactive metabolites in normal tissues, but it is not specifically indicated for doxorubicin-induced cardiotoxicity. *Carboplatin* - **Carboplatin** is a **platinum-based chemotherapy agent** similar to cisplatin, primarily used in the treatment of various cancers, including ovarian, lung, and head and neck cancers. - It causes myelosuppression and nephrotoxicity as major side effects but is a **chemotherapeutic drug itself**, not a protective agent against other chemotherapies. *Flucytosine* - **Flucytosine** is an **antifungal medication** used to treat severe systemic fungal infections, often in combination with amphotericin B. - Its mechanism involves interfering with fungal DNA and RNA synthesis, and it has no known role in mitigating the toxicity of doxorubicin.

Question 1

SIADH is associated with which of the following drugs?

Accepted Answer

Vincristine

Answer

Erythromycin

Answer

5-FU

Answer

Methotrexate

Question 2

Which drug has been used in the treatment of anaplastic thyroid carcinoma despite limited efficacy?

Accepted Answer

Doxorubicin

Answer

5-Fluorouracil

Answer

Methotrexate

Answer

Vinblastine

Question 3

Denileukin diftitox binds to which receptor?

Accepted Answer

IL-2 receptor

Answer

IL-1 receptor

Answer

IL-4 receptor

Answer

IL-5 receptor

Question 4

Use of tamoxifen for breast cancer can cause all of the following adverse effects, except which of the following?

Accepted Answer

Carcinoma in contralateral breast

Answer

Endometrial carcinoma

Answer

Cataract

Answer

Thromboembolism

Question 5

Which of the following chemotherapeutic agents can be administered orally?

Accepted Answer

Capecitabine

Answer

Actinomycin D

Answer

Doxorubicin

Answer

Cytarabine

Question 6

Which of the following can be given orally?

Accepted Answer

Cyclophosphamide

Answer

Actinomycin D

Answer

Cytosine arabinoside

Answer

Doxorubicin

Question 7

Tamoxifen is primarily indicated for reducing the risk of which type of cancer?

Accepted Answer

Breast

Answer

Endometrium

Answer

Ovary

Answer

All of the options

Question 8

Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?

Accepted Answer

Cisplatin

Answer

Cyclophosphamide

Answer

Methotrexate

Answer

Dacarbazine

Question 9

Which one of the following can cause agranulocytosis most commonly?

Accepted Answer

Alkylating agents

Answer

Paracetamol

Answer

Endotoxemia

Answer

Corticosteroids

Question 10

The use of which of the following helps in reducing the toxicity of doxorubicin to the heart?

Accepted Answer

Dexrazoxane

Answer

Amifostine

Answer

Carboplatin

Answer

Flucytosine

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?